Molecular Tumor Board 2020-21
Offered By: University of Barcelona via Coursera
Course Description
Overview
Se trata de un curso que nace a raíz de una de las sesiones formativas que realiza cada 15 días el Servicio de Oncología Médica del Hospital Clínic de Barcelona (HCB). En este curso se presentan casos clínicos simulando un MTB de tumores sólidos, con un objetivo principal, mejorar el conocimiento específico del impacto clínico del perfil molecular en tumores sólidos.
Está destinado a médicos oncólogos y a estudiantes y profesionales vinculados a la oncología médica. Cada seminario que conforma el curso lo presenta un profesional de una patología diferente del Servicio de Oncología Médica del HCB.
Syllabus
- GERMLIME - Breaking myths. Is lung cancer a hereditary disease?
- MESO - How can a typical EGFR+ case, became atypical
- BREAST - Is there any role for precision medicine in triple negative breast cancer?
- URO-MESO - Clinical and Mutational Lanscape of Lethal Castrate Resistant prostate Cancer
- LUNG - Off-label treatments really work?
- PANCREAS - Precision medicine, is not only about somatic
- COLON - Why doesn't immunotherapy work for everyone?
- UPPER GI - Screening molecular in orphan tumors
- BREAST - Beyond actionable mutations
Taught by
Dra. Laura Mezquita Perez and Dr. Aleix Prat Aparicio
Tags
Related Courses
一堂課讓你認識肺癌（Basic Concepts of Lung Cancer: Diagnosis and Treatment）National Taiwan University via Coursera ON DEMAND: Yale’s Review of Advances in Oncology Highlights from the ASCO® Annual Meeting 2021
Yale University via Independent Lung Cancer - The Most Comprehensive Explanation
Medicosis Perfectionalis via YouTube Coughing - Dr. Gerard W. Frank - UCLA Health Community Lecture
University of California, Los Angeles via YouTube Advances in Lung Cancer Treatment and Diagnosis from Stanford Health Care
Stanford University via YouTube